[Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].

A liposomal drug DaunoXome was used as a single agent for stage III-IV breast cancer in 9 patients. Response was recorded in 6; partial regression of tumor--3, and stabilization of disease--in 3 cases. Nausea and vomiting were among the most frequent side-effects; stage I leukopenia was observed in 4; stage II--3, stage III--2 patients. No cardiotoxicity was reported.